Reported 23 days ago
Truist Financial has reduced its price target for AbCellera Biologics (NASDAQ:ABCL) from $28 to $10, while keeping a Buy rating. This adjustment follows AbCellera's fiscal Q1 2025 results, where it reported $4.2 million in revenue and a net loss of $45.6 million. The firm expresses optimism about AbCellera's clinical pipeline and its transition to a clinical-stage biotech, although it also notes that some AI stocks may present better investment opportunities.
Source: YAHOO